Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Regenxbio Inc (RGNX)

Regenxbio Inc (RGNX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,605,889
  • Shares Outstanding, K 36,807
  • Annual Sales, $ 218,510 K
  • Annual Income, $ 99,940 K
  • 60-Month Beta 0.86
  • Price/Sales 7.08
  • Price/Cash Flow 16.36
  • Price/Book 3.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.40
  • Number of Estimates 3
  • High Estimate 0.25
  • Low Estimate -1.19
  • Prior Year 0.04
  • Growth Rate Est. (year over year) -1,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
35.88 +21.60%
on 11/14/19
45.88 -4.90%
on 12/09/19
+7.03 (+19.21%)
since 11/13/19
3-Month
33.04 +32.05%
on 09/27/19
45.88 -4.90%
on 12/09/19
+5.71 (+15.06%)
since 09/13/19
52-Week
30.38 +43.61%
on 09/09/19
63.21 -30.98%
on 03/20/19
-2.40 (-5.21%)
since 12/13/18

Most Recent Stories

More News
REGENXBIO to Present at the Evercore ISI 2nd Annual HealthCONx Conference

REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform,...

RGNX : 43.63 (+3.86%)
Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates

Regenxbio (RGNX) delivered earnings and revenue surprises of -3.30% and 97.18%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

RGNX : 43.63 (+3.86%)
Regenxbio: 3Q Earnings Snapshot

ROCKVILLE, Md. (AP) _ Regenxbio Inc. (RGNX) on Tuesday reported a loss of $34.6 million in its third quarter.

RGNX : 43.63 (+3.86%)
REGENXBIO Reports Third Quarter 2019 Financial and Operating Results and Recent Operational Highlights

-- Initiation of RGX-314 Phase IIb trial for wet AMD and IND filing for Phase II trial in diabetic retinopathy now expected in Q1 2020 as a result of partial clinical hold following FDA notification related...

RGNX : 43.63 (+3.86%)
Clearside Biomedical Announces Option Exercise by REGENXBIO for Global License for Use of SCS Microinjector(TM) in AAV Gene Therapy Delivery

Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases,...

CLSD : 1.81 (+4.62%)
RGNX : 43.63 (+3.86%)
REGENXBIO To Host Conference Call on November 5 to Discuss Third Quarter 2019 Financial Results and Recent Operational Highlights

REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform,...

RGNX : 43.63 (+3.86%)
REGENXBIO Announces Presentations at the European Society of Gene & Cell Therapy 27th Annual Congress

REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform,...

RGNX : 43.63 (+3.86%)
Ultragenyx's (RARE) NDA for LC-FAOD Drug Accepted by FDA

Ultragenyx (RARE) announces FDA's acceptance of the NDA for UX007 for the treatment of LC-FAOD.

BAYRY : 19.7800 (+1.59%)
INCY : 91.51 (-1.44%)
RARE : 42.73 (+0.02%)
RGNX : 43.63 (+3.86%)
REGENXBIO Announces Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting

REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform,...

RGNX : 43.63 (+3.86%)
Wet AMD Space in Focus: New Drug Approvals & Key Advancements

The FDA approval of Novartis' Beovu for wet AMD brings this space to focus. Let us assess the recent key developments in the area.

RHHBY : 38.1600 (-0.73%)
BAYRY : 19.7800 (+1.59%)
AGN : 188.34 (+0.04%)
NVS : 92.99 (-0.08%)
REGN : 376.42 (+1.14%)
RGNX : 43.63 (+3.86%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Trade RGNX with:

Business Summary

REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver...

See More

Key Turning Points

2nd Resistance Point 45.10
1st Resistance Point 44.37
Last Price 43.63
1st Support Level 42.30
2nd Support Level 40.96

See More

52-Week High 63.21
Fibonacci 61.8% 50.67
Fibonacci 50% 46.79
Last Price 43.63
Fibonacci 38.2% 42.92
52-Week Low 30.38

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar